A total of 420 travelers were given the TRID2 course over a period of approximately 3.5 years from June 2007 to November 2010, with 227 (54%) females, and 193 (46%) were males. The mean age was 32.4 years, with a range of 10 to 65 years. Most travelers (63.8%) received the Galunisertib nmr “TRID2 standard” schedule, and there were no significant differences in age and sex distribution between the “TRID2 standard” group, and the “TRID2 nonstandard” group. Figure 1 shows the age distribution of travelers in this case series, by “TRID2 standard” and “TRID2 nonstandard” schedules status. For travelers

who received the “TRID2 nonstandard” schedule, the time interval between clinic visits 1 and 2 ranged from 6 to 30 days,

with a median of 8 days; and the time interval between clinic visit 2 and serology ranged from 2 to 37 days, with a median of 21 days. Compliance with serology was 100%, and the overall seroconversion rate was 94.5% (95% CI: 91.9 to 96.5) at clinic visit 3, with no significant difference between males and females. Seroconversion rate was significantly lower with increasing age (correlation coefficient = −0.05, p < 0.001), and rates for each age group are shown in Figure 2. The seroconversion rate was 94.4% (95% CI: 90.9–96.8) in the “TRID2 standard” group, and 94.7% (95% CI: 89.9–97.7) in the “TRID2 nonstandard” group. There was no significant difference in seroconversion rates between the selleck chemicals llc two groups (χ2 = 0.02, p = 0.89). In addition, there was no difference in seroconversion rates between “TRID2 standard” and “TRID2 nonstandard” cases in any of the age groups. The time interval between clinic visits 1 and 2 in this study did not have any significant effect on seroconversion rates (correlation coefficient = 0.03, p = 0.78). The seroconversion rate was higher in those who had their serology performed later, but this was not statistically significant (correlation coefficient = 0.06, p = 0.15). The variation in P-type ATPase seroconversion rates

with the timing of serology is shown in Figure 3. Of the 420 cases, 23 (5.5%) had antibody levels below 0.5 IU/mL, and were considered nonimmune. The distribution of antibody levels measured at clinic visit 3 is shown in Figure 4. Females had significantly higher antibody levels than males (χ2 = 11.96, p = 0.02), but the clinical significance of this finding is uncertain. The percentage of cases in each antibody category for males and females is shown in Figure 4. Antibody levels were significantly lower in the older age groups (χ2 = 41.30, p = 0.003), and the variation in antibody levels between age groups is shown in Figure 5. There were no significant differences in antibody levels with variations in vaccine schedule (χ2 = 4.83, p = 0.30), the timing of clinic visit 2 (correlation coefficient = 0.07, p = 0.09), or the timing of serology (χ2 = 11.84, p = 0.76).